

## **Pharmacy Drug Policy Checklist**

POLICY NAME Chenodal (chenodiol) POLICY # 3235P

## Criteria

Coverage Criteria for Gallstone Dissolution	
	Documented diagnosis of radiolucent gallstones in well-opacifying gallbladders
	<ul> <li>Documentation to support stones are not calcified (radiopaque) or radiolucent bile pigment stones</li> </ul>
	Patient is not a candidate for surgery
	Prescribed by or in consultation with a gastroenterologist (stomach doctor)
	Previous trial and failure, intolerance or contraindication to ursodiol
Cov	erage Criteria for Cerebrotendinous Xanthomatosis (CTX)
	crugo oritoria for ociebroterialifous Adritifornatosis (OTA)
	Diagnosis of cerebrotendinous xanthomatosis as confirmed by genetic testing with evidence of pathogenic CYP27A1 variants
	Diagnosis of cerebrotendinous xanthomatosis as confirmed by genetic testing with evidence of
	Diagnosis of cerebrotendinous xanthomatosis as confirmed by genetic testing with evidence of pathogenic CYP27A1 variants
□ □	Diagnosis of cerebrotendinous xanthomatosis as confirmed by genetic testing with evidence of pathogenic CYP27A1 variants
□ □ Exc	Diagnosis of cerebrotendinous xanthomatosis as confirmed by genetic testing with evidence of pathogenic CYP27A1 variants  Prescribed by or in consultation with a metabolic specialist (metabolism doctor)
Exc	Diagnosis of cerebrotendinous xanthomatosis as confirmed by genetic testing with evidence of pathogenic CYP27A1 variants  Prescribed by or in consultation with a metabolic specialist (metabolism doctor)  Jusion Criteria – Any of the following prevents coverage